Literature DB >> 18955981

Unrelated cord blood transplantation after myeloablative conditioning in adults with ALL.

J Ooi1, S Takahashi, A Tomonari, N Tsukada, T Konuma, S Kato, S Kasahara, A Sato, F Monma, F Nagamura, T Iseki, A Tojo, S Asano.   

Abstract

We analyzed the disease-specific outcomes of adult ALL treated with cord blood transplantation (CBT) after myeloablative conditioning. Between October 2000 and November 2007, 27 adult patients with ALL were treated with unrelated CBT. All patients received four fractionated 12 Gy TBI and chemotherapy as myeloablative conditioning. The median age was 36 years, the median weight was 57 kg and the median number of nucleated cells was 2.47 x 10(7)/kg. All patients received a single and HLA-mismatched cord blood unit. The cumulative incidence of neutrophil recovery at day 30 and platelet recovery at day 200 was 92.6 and 92.3%, respectively. With a median follow-up of 47 months, the probability of EFS at 5 years was 57.2%. The 5-year cumulative incidence of TRM and relapse was 3.7 and 27.4%, respectively. These results suggest that unrelated CBT after myeloablative conditioning could be safely and effectively used for adult patients with ALL.

Entities:  

Mesh:

Year:  2008        PMID: 18955981     DOI: 10.1038/bmt.2008.347

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Authors:  Junya Kanda; David A Rizzieri; Cristina Gasparetto; Gwynn D Long; John P Chute; Keith M Sullivan; Ashley Morris; Clayton A Smith; Donna E Hogge; Janet Nitta; Kevin Song; Donna Niedzwiecki; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-22       Impact factor: 5.742

2.  Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  L Tucunduva; A Ruggeri; G Sanz; S Furst; G Socié; M Michallet; W Arcese; N Milpied; I Yakoub-Agha; W Linkesch; J Cornelissen; L Mannone; A P Iori; J-M Ribera; J Sanz; P Montesinos; D Purtill; M Labopin; E Gluckman; M Mohty; V Rocha
Journal:  Bone Marrow Transplant       Date:  2014-07       Impact factor: 5.483

3.  High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study.

Authors:  Y Arai; T Kondo; A Shigematsu; J Tanaka; S Takahashi; T Kobayashi; N Uchida; Y Onishi; J Ishikawa; H Kanamori; M Sawa; A Yokota; Y Kouzai; M Takanashi; T Ichinohe; Y Atsuta; S Mizuta
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

Review 4.  Challenges in umbilical cord blood stem cell banking for stem cell reviews and reports.

Authors:  Karen Ballen
Journal:  Stem Cell Rev Rep       Date:  2010-03       Impact factor: 5.739

5.  Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies.

Authors:  T L Kindwall-Keller; Y Hegerfeldt; H J Meyerson; S Margevicius; P Fu; W van Heeckeren; H M Lazarus; B W Cooper; S L Gerson; P Barr; W W Tse; C Curtis; L R Fanning; R J Creger; J M Carlson-Barko; M J Laughlin
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.